Kinnari Patel
President bij ROCKET PHARMACEUTICALS, INC.
Vermogen: 11 M $ op 31-05-2024
Actieve functies van Kinnari Patel
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Operationeel Directeur | 04-01-2018 | - |
| Hoofd Techniek/Wetenschap/O&O | 27-03-2024 | - | |
| President | - | - |
Loopbaan van Kinnari Patel
Eerdere bekende functies van Kinnari Patel
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Operationeel Directeur | 01-01-2018 | 01-02-2021 |
| Algemeen Adviseur | 01-04-2016 | 01-12-2017 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-11-2010 | 01-04-2014 |
Opleiding van Kinnari Patel
| The Leonard N Stern School of Business | Masters Business Admin |
| University of the Sciences in Philadelphia | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Chief Operating Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Beurs
- Insiders
- Kinnari Patel
- Ervaring
